



# Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 05 August 2023

Ref. No.: TCPCL/SEC/2023-24/00039

**To,**  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001  
**Scrip Code: 543321**

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla, Complex Bandra(E),  
Mumbai-400 051  
**Scrip Symbol: TATVA**

**Subject: Newspaper Publication of extract of financial results of the Company**

Dear Sir/Madam,

Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter ended 30 June 2023, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 05 August 2023.

The above information shall be made available on the website of the Company at [www.tatvachintan.com](http://www.tatvachintan.com).

Kindly take the same on record and disseminate to the public at large.

Thanking You,

Your Faithfully,  
**For Tatva Chintan Pharma Chem Limited**

**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**

Encl.: As above

**Registered Office and Factory :** Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

**Dahej SEZ Unit :** Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

**Corporate Office and R & D Center (DSIR Approved) :** Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

**Telephone No. :** +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** [cs@tatvachintan.com](mailto:cs@tatvachintan.com) **Website :** [www.tatvachintan.com](http://www.tatvachintan.com)



# TATVA CHINTAN PHARMA CHEM LIMITED

CIN: L24232GJ1996PLC029894

Registered Office : Plot No. 502 / 17, GIDC Estate, Ankleshwar, Dist. Bharuch, Gujarat - 393 002

Website : www.tatvachintan.com E-mail : cs@tatvachintan.com Tel. No. : +91 75748 48533

## EXTRACT OF CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023

(Currency: Indian Rupees in Million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Total income from operations	1,143.64	1,245.11	884.02	4,236.12
2.	Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items)	134.20	113.89	136.95	483.66
3.	Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items)	134.20	78.02	136.95	447.79
4.	Net profit / (loss) for the period after tax (after exceptional and/or extraordinary items)	95.04	169.54	97.97	454.87
5.	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	94.03	170.75	99.00	461.35
6.	Equity share capital	221.65	221.65	221.65	221.65
7.	Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year	-	-	-	4,926.26
8.	Earnings per share (of Rs. 10/- each) (not annualised)				
	- Basic:	4.29	7.65	4.42	20.52
	- Diluted:	4.29	7.65	4.42	20.52

## KEY NUMBERS OF STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023

(Currency: Indian Rupees in Million)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Total income from operations	1,061.05	1,194.06	860.65	4,030.44
2.	Net profit before tax (before exceptional items)	117.19	104.77	119.76	424.18
3.	Net profit before tax (after exceptional items)	117.19	68.90	119.76	388.31
4.	Net profit after tax	82.48	161.54	85.00	404.65
5.	Total comprehensive income	82.16	161.96	84.57	403.36

### Notes:

- The Consolidated & Standalone Financial Results for the quarter ended 30 June 2023, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 04 August 2023.
- The above is an extract of the detailed format of Financial Results for the quarter ended 30 June 2023, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of Financial Results for the quarter ended 30 June 2023, are available on the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and also on the Company's website at www.tatvachintan.com.
- Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of  
Tatva Chintan Pharma Chem Limited

Sd/-

Chintan N. Shah

Chairman and Managing Director

DIN: 00183618

Place : Vadodara, Gujarat, India.

Date : 04 August 2023

Ahmedabad

Sr. No.		Particulars	Quarter ended		Year ended	
			30.06.2023 (Unaudited)	31.03.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1.	Total income from operations		1,143.64	1,245.11	884.02	4,236.12
2.	Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items)		134.20	113.89	136.95	483.66
3.	Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items)		134.20	78.02	136.95	447.79
4.	Net profit / (loss) for the period after tax (after exceptional and/or extraordinary items)		95.04	169.54	97.97	454.87
5.	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]		94.03	170.75	99.00	461.35
6.	Equity share capital		221.65	221.65	221.65	221.65
7.	Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year		-	-	-	4,926.26
8.	Earnings per share (of Rs. 10/- each) (not annualised)					
	- Basic:		4.29	7.65	4.42	20.52
	- Diluted:		4.29	7.65	4.42	20.52

**EXTRACT OF CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023**

(Currency: Indian Rupees in Million, except per share data)

Sr. No.		Particulars	Quarter ended		Year ended	
			30.06.2023 (Unaudited)	31.03.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1.	Total income from operations		1,061.05	1,194.06	860.65	4,030.44
2.	Net profit before tax (before exceptional items)		117.19	104.77	119.76	424.18
3.	Net profit before tax (after exceptional items)		117.19	68.90	119.76	388.31
4.	Net profit after tax		82.48	161.54	85.00	404.65
5.	Total comprehensive income		82.16	161.96	84.57	403.36

**KEY NUMBERS OF STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023**

(Currency: Indian Rupees in Million)

**Notes:**

- The Consolidated & Standalone Financial Results for the quarter ended 30 June 2023, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 04 August 2023.
- The above is an extract of the detailed format of Financial Results for the quarter ended 30 June 2023, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of Financial Results for the quarter ended 30 June 2023, are available on the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and also on the Company's website at [www.tatvachintan.com](http://www.tatvachintan.com).
- Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

**For and on behalf of the Board of Directors of  
Tatva Chintan Pharma Chem Limited**  
Sd/-  
**Chintan N. Shah**  
**Chairman and Managing Director**  
DIN: 00183618

Place : Vadodara, Gujarat, India.  
Date : 04 August 2023